Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRS-344/S095012 in Advanced Solid Tumors
NCT05159388Phase 2Terminated
- Sponsor
- Servier
- Start
- Sep 2021
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of PRS-344 in solid tumor, sponsored by Servier. Primary endpoints: Number of Participants With at Least One Dose-Limiting Toxicity at 28 days, Number of Participants With at Least One Adverse Event at 3.5 years and 1 more. Started Sep 2021; status: terminated.
02
Drugs
PRS-344
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05159388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159388.